Top

European Archives of Oto-Rhino-Laryngology

Published in:

Open Access 01-03-2012 | Head and Neck

Chemoradiation for advanced hypopharyngeal carcinoma: a retrospective study on efficacy, morbidity and quality of life

Authors: Stijn Keereweer, Jeroen D. F. Kerrebijn, Abrahim Al-Mamgani, Aniel Sewnaik, Robert J. Baatenburg de Jong, Esther van Meerten

Published in: European Archives of Oto-Rhino-Laryngology | Issue 3/2012

Abstract

Chemoradiation (CRT) is a valuable treatment option for advanced hypopharyngeal squamous cell cancer (HSCC). However, long-term toxicity and quality of life (QOL) is scarcely reported. Therefore, efficacy, acute and long-term toxic effects, and long-term QOL of CRT for advanced HSCC were evaluated,using retrospective study and post-treatment quality of life questionnaires. in a tertiary hospital setting. Analysis was performed of 73 patients that had been treated with CRT. Toxicity was rated using the CTCAE score list. QOL questionnaires EORTC QLQ-C30, QLQ-H&N35, and VHI were analyzed. The most common acute toxic effects were dysphagia and mucositis. Dysphagia and xerostomia remained problematic during long-term follow-up. After 3 years, the disease-specific survival was 41%, local disease control was 71%, and regional disease control was 97%. The results indicated that CRT for advanced HSCC is associated with high locoregional control and disease-specific survival. However, significant acute and long-term toxic effects occur, and organ preservation appears not necessarily equivalent to preservation of function and better QOL.

Bova R, Goh R, Poulson M, Coman WB (2005) Total pharyngolaryngectomy for squamous cell carcinoma of the hypopharynx: a review. Laryngoscope 115:864–869PubMedCrossRef

Keereweer S, de Wilt JH, Sewnaik A, Meeuwis CA, Tilanus HW, Kerrebijn JD (2010) Early and long-term morbidity after total laryngopharyngectomy. Eur Arch Otorhinolaryngol 267(9):1437–1444

[Anonymous] (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324: 1685–1690

Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud TLarynx (1996) Preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890–899PubMedCrossRef

Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098PubMedCrossRef

Pignon JP, le Maître A, Maillard E, Bourhis J (2009) MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92(1):4–14 Epub 2009 May 14PubMedCrossRef

Boscolo-Rizzo P, Maronato F, Marchiori C, Gava A, Da Mosto MC (2008) Long-term quality of life after total laryngectomy and postoperative radiotherapy versus concurrent chemoradiotherapy for laryngeal preservation. Laryngoscope 118:300–306PubMedCrossRef

Hanna E, Sherman A, Cash D et al (2004) Quality of life for patients following total laryngectomy vs chemoradiation for laryngeal preservation. Arch Otolaryngol Head Neck Surg 130:875–879PubMedCrossRef

Trivedi NP, Swaminathan DK, Thankappan K, Chatni S, Kuriakose MA, Iyer S (2008) Comparison of quality of life in advanced laryngeal cancer patients after concurrent chemoradiotherapy vs total laryngectomy. Otolaryngol Head Neck Surg 139:702–707PubMedCrossRef

10.

Lambert L, Fortin B, Soulieres D et al (2010) Organ preservation with concurrent chemoradiation for advanced laryngeal cancer: are we succeeding? Int J Radiat Oncol Biol Phys 76:398–402PubMedCrossRef

11.

Nguyen NP, Sallah S, Karlsson U, Antoine JE (2002) Combined chemotherapy and radiation therapy for head and neck malignancies: quality of life issues. Cancer 94:1131–1141PubMedCrossRef

12.

Piccirillo JF, Costas I (2004) The impact of comorbidity on outcomes. ORL J Otorhinolaryngol Relat Spec 66:180–185PubMedCrossRef

13.

Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181PubMedCrossRef

14.

Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRef

15.

Bjordal K, Hammerlid E, Ahlner-Elmqvist M et al (1999) Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 17:1008–1019PubMed

16.

Jacobson B, Johnson A, Grywalsky C et al (1997) The voice handicap index (VHI): development and validation. Am J Speech Language Pathol 6:66–70

17.

Hanna E, Alexiou M, Morgan J et al (2004) Intensive chemoradiotherapy as a primary treatment for organ preservation in patients with advanced cancer of the head and neck: efficacy, toxic effects, and limitations. Arch Otolaryngol Head Neck Surg 130:861–867PubMedCrossRef

18.

Tai SK, Yang MH, Wang LW et al (2008) Chemoradiotherapy laryngeal preservation for advanced hypopharyngeal cancer. Jpn J Clin Oncol 38:521–527PubMedCrossRef

19.

Urba SG, Moon J, Giri PG et al (2005) Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial. J Clin Oncol 23:88–95PubMedCrossRef

20.

Vokes EE, Kies MS, Haraf DJ et al (2000) Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 18:1652–1661PubMed

21.

Chen AM, Li BQ, Lau DH et al (2010) Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 78:1026–1032PubMedCrossRef

22.

Corry J, Poon W, McPhee N et al (2009) Prospective study of percutaneous endoscopic gastrostomy tubes versus nasogastric tubes for enteral feeding in patients with head and neck cancer undergoing (chemo)radiation. Head Neck 31:867–876PubMedCrossRef

23.

Pfister DG, Su YB, Kraus DH et al (2006) Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24:1072–1078PubMedCrossRef

24.

Van der Molen L, Van Rossum MA, Burkhead LM, Smeele LE, Hilgers FJ (2009) Functional outcomes and rehabilitation strategies in patients treated with chemoradiotherapy for advanced head and neck cancer: a systematic review. Eur Arch Otorhinolaryngol 266(6):901–902CrossRef

25.

Machtay M, Moughan J, Trotti A et al (2008) Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 26(21):3582–3589 Epub 2008 Jun 16PubMedCrossRef

26.

Logemann JA, Smith CH, Pauloski BR et al (2001) Effects of xerostomia on perception and performance of swallow function. Head Neck 23:317–321PubMedCrossRef

27.

Chaplin JM, Morton RP (1999) A prospective, longitudinal study of pain in head and neck cancer patients. Head Neck 21:531–537PubMedCrossRef

28.

Evans E, Carding P, Drinnan M (2009) The voice handicap index with post-laryngectomy male voices. Int J Lang Commun Disord 44:575–586PubMedCrossRef

29.

Winquist E, Oliver T, Gilbert R (2007) Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: a systematic review with meta-analysis. Head Neck 29:38–46PubMedCrossRef

30.

Adelstein DJ, Moon J, Hanna E et al (2010) Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: a Southwest Oncology Group phase II trial (S0216). Head Neck 32:221–228PubMed

31.

Yoo GH, Moon J, LeBlanc M et al (2009) A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Arch Otolaryngol Head Neck Surg 135:869–874PubMedCrossRef

Title: Chemoradiation for advanced hypopharyngeal carcinoma: a retrospective study on efficacy, morbidity and quality of life
Authors: Stijn Keereweer
Jeroen D. F. Kerrebijn
Abrahim Al-Mamgani
Aniel Sewnaik
Robert J. Baatenburg de Jong
Esther van Meerten
Publication date: 01-03-2012
Publisher: Springer-Verlag
Published in: European Archives of Oto-Rhino-Laryngology / Issue 3/2012
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-011-1694-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Chemoradiation for advanced hypopharyngeal carcinoma: a retrospective study on efficacy, morbidity and quality of life

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

OLAF: standardization of international olfactory tests

Anesthesia for tracheobronchial foreign bodies removal via self-retaining laryngoscopy and Hopkins telescopy in children

Bilateral aplasia of paranasal sinuses

Comparison between Gelfoam packing and no packing after endoscopic sinus surgery in the same patients

Experience with combination of cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma

Clinical pathological analysis of nine cases of aneurysmal bone cyst of the jaws in a Brazilian population